Alternatives to Surfacer Inside-Out — Restore Access. Preserve Options.
Patients searching for Surfacer Inside-Out alternatives are typically facing chronically occluded central veins and need reliable options beyond moving to secondary access sites. The Surfacer Inside-Out Access Catheter System was designed specifically to restore right internal jugular access from the inside out, avoiding damage to remaining veins and enabling better long-term AV fistula or graft placement. Clinicians exploring alternatives often compare procedural success rates, invasiveness, and impact on hemodialysis costs. Common alternatives range from traditional tunneled catheters and surgical bypass to other specialized grafts and access devices. Understanding how each option handles total occlusions, preserves future access sites, and supports permanent dialysis access helps providers choose the best path for reducing morbidity and catheter-related complications in complex venous occlusion cases.
Covera is a covered stent specifically indicated for treatment of stenoses in arteriovenous fistulas and grafts. It provides targeted luminal support at lesion sites. In comparison to VenoStent's investigational external wrap, Covera is an internal, permanent endovascular solution already on the market. It is chosen for focal lesions rather than global fistula support. Searchers often review it when mapping current commercial devices against future bioengineered approaches.
HeRO GraftThe HeRO Graft is a fully subcutaneous hybrid vascular access device used for hemodialysis patients with central venous occlusion who cannot receive conventional upper-arm fistulas or grafts. It combines an ePTFE graft with a nitinol-reinforced venous outflow component that bypasses stenosed central veins to the right atrium. Unlike VenoStent's investigational bioabsorbable wrap intended to support maturing fistulas, HeRO is immediately available, surgically implanted, and reimbursed today. It serves a narrower rescue-access population rather than prophylactic support of new fistulas. Long-term data show acceptable patency but higher infection rates than native vessels. Relevance to VenoStent searchers is high when central venous disease precludes standard options.
VenoStentThe HeRO Graft is a fully subcutaneous hybrid vascular access device used for hemodialysis patients with central venous occlusion who cannot receive conventional upper-arm fistulas or grafts. It combines an ePTFE graft with a nitinol-reinforced venous outflow component that bypasses stenosed central veins to the right atrium. Unlike VenoStent's investigational bioabsorbable wrap intended to support maturing fistulas, HeRO is immediately available, surgically implanted, and reimbursed today. It serves a narrower rescue-access population rather than prophylactic support of new fistulas. Long-term data show acceptable patency but higher infection rates than native vessels. Relevance to VenoStent searchers is high when central venous disease precludes standard options.
Gore AcusealPropaten is a heparin-bonded ePTFE vascular graft intended to reduce thrombosis in peripheral and dialysis applications. It offers improved patency over standard PTFE in some studies. Compared with VenoStent's resorbable external wrap designed to enhance native fistula biology, Propaten is a permanent synthetic conduit used when autologous options are exhausted. It is widely available and reimbursed. The product serves a different clinical niche but appears in alternative searches focused on lowering access failure rates today.
FlixeneFlixene is a trilaminate ePTFE graft engineered for early cannulation in dialysis access. It reduces time to first use compared with standard grafts. Unlike the bioabsorbable concept behind SelfWrap, Flixene remains permanently implanted. It is commercially distributed and positioned for patients needing rapid access creation. Relevance exists for those exploring all synthetic graft alternatives while VenoStent completes trials.